Saturday 17 October 2026
Export SCLX’s income statement to Excel — free account
Scilex Holding Company
SCLX Healthcare Drug Manufacturers General
Scilex Holding Company’s revenue for fiscal 2025 (year ended December 2025) was $30.3 million, down 46.5% from fiscal 2024. In the quarter to June 2026, revenue fell 22.8%, EPS fell 124.4%, free cash flow fell 203.8% and total debt rose 102.7%, each against the same quarter a year earlier.
2.83
0.01
+0.35%
Follow SCLX
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | — | 212.92 | 62.55 | 19.61 | 8.28 | 2.24 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | — | 233.41 | 243.43 | 368.31 | 57.32 | 21.34 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | 2 | 2 | 90 | 105 | 115 | 34 | ||||
| Revenue/emp, $m | — | — | — | — | 11.78 | 15.66 | 0.42 | 0.45 | 0.49 | 0.89 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | 24 | 31 | 38 | 47 | 57 | 30 | ||||
| Gross margin, % | — | — | — | — | 90.88 | 88.40 | 71.61 | 66.45 | 70.51 | 64.97 | |||||
| EBT | — | — | — | — | (48) | (88) | (23) | (114) | (73) | (374) | |||||
| EBT margin, % | — | — | — | — | (201.92) | (282.34) | (61.42) | (244.57) | (128.66) | (1,236.33) | |||||
| Net income | — | 0 | — | — | (48) | (88) | (23) | (114) | (73) | (374) | |||||
| Depreciation | — | — | — | — | 14 | 12 | 7 | 4 | 4 | 78 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | — | — | 6.20 | 8.24 | 9.91 | 12.54 | 5.62 | 2.74 | ||||
| Earnings | — | — | — | — | (12.50) | (23.27) | (6.09) | (44.75) | (7.24) | (36.48) | |||||
| Cash flow | — | — | — | — | (8.28) | (7.54) | (5.54) | (5.56) | 1.92 | 0.35 | |||||
| Capex | — | — | — | — | (0.01) | 0.00 | 0.00 | (0.01) | 0.00 | (0.01) | |||||
| Free cash flow | — | — | — | — | (8.28) | (7.54) | (5.54) | (5.56) | 1.92 | 0.33 | |||||
| Book value | — | — | — | — | 0.00 | (58.92) | 9.44 | (46.41) | (19.15) | (19.19) | |||||
| Shares, m | — | — | — | — | 4 | 4 | 4 | 4 | 10 | 11 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| P/S | — | — | — | — | 0.00 | 0.00 | 11.69 | 3.54 | 1.65 | 2.77 | |||||
| P/B | — | — | — | — | 198,015.24 | 0.00 | 12.27 | 0.00 | 0.00 | 0.00 | |||||
| EV/Sales | — | — | — | — | 0.00 | 0.00 | 11.78 | 5.89 | 2.22 | 5.19 | |||||
| EV/FCF | — | — | — | — | 0.00 | (33.51) | (21.07) | (13.27) | 6.51 | 42.97 | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | (31) | (29) | (21) | (21) | 19 | 4 | ||||
| Capex | — | — | — | — | 0 | — | 0 | 0 | — | 0 | |||||
| Free cash flow | — | — | — | — | (31) | (29) | (21) | (21) | 19 | 4 | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | — | — | 0 | (146) | (15) | (204) | (218) | (445) | ||||
| Total debt | — | — | — | — | 0 | 133 | 1 | 108 | 35 | 83 | |||||
| Net debt | — | — | — | — | 0 | 129 | (2) | 105 | 32 | 72 | |||||
| Shareholders’ equity | — | — | — | — | 0 | (224) | 36 | (173) | (193) | (212) | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | — | — | (23,819.05) | (226.35) | (28.41) | (177.79) | (74.96) | (175.78) | ||||
| ROIC | — | — | — | — | 0.00 | 0.00 | (92.93) | 0.00 | 0.00 | 0.00 | |||||
| ROE | — | — | — | — | (254,112.30) | 79.00 | 24.90 | 244.29 | 39.83 | 199.06 | |||||
Negative figures in brackets.
Fiscal years to Dec 2025 · latest quarter Jun 2026
Charts ten years each
Scilex Holding Company vs peers in Drug Manufacturers General (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| SNY Sanofi | $96.0B | 21.3× | — | +17.35% (above 0%: growing) | −90.76% (below 0%: shrinking) | −45.06% (below 0%: shrinking) | 75.47% | 17.48% | Compare |
| BIIB Biogen Inc. | $34.8B | 41.0× | 31.5× | +3.42% (above 0%: growing) | −84.76% (below 0%: shrinking) | +103.28% (above 0%: growing) | 71.60% | 5.52% | Compare |
| OGN Organon & Co. | $3.6B | 17.4× | 5.2× | −2.26% (below 0%: shrinking) | −26.79% (below 0%: shrinking) | −82.97% (below 0%: shrinking) | 54.36% | 20.67% | Compare |
| GRFS Grifols, S.A. | $2.0B | 8.5× | — | +5.76% (above 0%: growing) | +466.92% (above 0%: growing) | +300.52% (above 0%: growing) | 36.47% | 14.76% | Compare |
| AMRN Amarin Corporation PLC | $244.4M | — (loss-making) | — (loss-making) | −41.97% (below 0%: shrinking) | n/m | −60.23% (below 0%: shrinking) | 35.51% | (28.45%) | Compare |
| NSRX Nasus Pharma Ltd. | $37.1M | — | — | — | — | −486.98% (below 0%: shrinking) | — | — | Compare |
| MIRA MIRA Pharmaceuticals, Inc. | $27.7M | — (loss-making) | — | — | n/m | −50.76% (below 0%: shrinking) | — | 0.00% | Compare |
| SCLX Scilex Holding Company | $19.8M | — (loss-making) | — (loss-making) | −22.78% (below 0%: shrinking) | n/m | −203.76% (below 0%: shrinking) | 51.88% | (385.02%) | |
| MDCX Medicus Pharma Ltd | $6.3M | — (loss-making) | — | — | n/m | −27.70% (below 0%: shrinking) | — | 0.00% | Compare |
| Median of peers | $1.1B | 19.3× | — | +3.42% | −55.77% | −47.91% | 54.36% | 5.52% |
Scilex Holding Company (SCLX) key facts
- Concern: Scilex Holding Company’s revenue for fiscal 2025 (year ended December 2025) was $30.3 million, down 46.5% from fiscal 2024.
- Scilex Holding Company (SCLX) is a Drug Manufacturers General company in the Healthcare sector, listed on Nasdaq.
- As of October 16, 2026, SCLX traded at $2.83, a market capitalization of $19.8 million.
- Return on equity was 199.1% and debt-to-equity -0.26.
- Its Piotroski F-score is 3 out of 9 and its Altman Z-score is −7.96 (distress zone) for fiscal 2025.